Search

Sanjay Bhanot

age ~59

from Carlsbad, CA

Also known as:
  • Sanjay Bhandt
  • Puja Bhanot
8094 Paseo Arrayan, Carlsbad, CA 92009760-6326305

Sanjay Bhanot Phones & Addresses

  • 8094 Paseo Arrayan, Carlsbad, CA 92009 • 760-6326305
  • 7975 Paseo Aliso, Carlsbad, CA 92009 • 760-6326305
  • 1066 Cottage Way, Encinitas, CA 92024 • 760-6326305
  • San Diego, CA

Education

  • Degree:
    Associate degree or higher

Emails

Resumes

  • Sanjay Bhanot Photo 1

    Vice President Metabolic Diseases R&Amp;D At Isis Pharmaceuticals

    view source
  • Position:
    Vice President Metabolics & Translational Medicine at Isis Pharmaceuticals
  • Location:
    Greater San Diego Area
  • Industry:
    Biotechnology
  • Work:
    Isis Pharmaceuticals since Jan 2000
    Vice President Metabolics & Translational Medicine

Us Patents

  • Modulation Of Glucagon Receptor Expression

    view source
  • US Patent:
    7399853, Jul 15, 2008
  • Filed:
    Apr 27, 2004
  • Appl. No.:
    10/832777
  • Inventors:
    Susan M. Freier - San Diego CA,
    Kenneth W. Dobie - Del Mar CA,
    Sanjay Bhanot - Carlsbad CA,
    Robert McKay - Poway CA,
  • Assignee:
    ISIS Pharmaceuticals - Carlsbad CA
  • International Classification:
    C07H 21/04
    C12Q 1/68
    C12N 15/85
  • US Classification:
    536 245, 435 6, 435325
  • Abstract:
    Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
  • Methods For Use In Modulating Mir-122A

    view source
  • US Patent:
    2007004, Mar 1, 2007
  • Filed:
    Aug 29, 2006
  • Appl. No.:
    11/513102
  • Inventors:
    Christine Esau - La Jolla CA,
    Sanjay Bhanot - Carlsbad CA,
  • International Classification:
    A61K 48/00
  • US Classification:
    514044000
  • Abstract:
    Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods employ oligomeric compounds which hybridize with or sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid comprising or encoding miR-122a.
  • Antisense Modulation Of Ptp1B Expression

    view source
  • US Patent:
    2009003, Feb 5, 2009
  • Filed:
    Oct 13, 2005
  • Appl. No.:
    11/665423
  • Inventors:
    Sanjay Bhanot - Carlsbad CA,
    Brett P. Monia - Encinitas CA,
    Richard S. Geary - Carlsbad CA,
    Lise Lunt Kjems - Encinitas CA,
  • International Classification:
    A61K 38/28
    A61K 31/711
    A61P 3/10
    A61P 3/04
    A61P 9/10
  • US Classification:
    514 4, 514 44
  • Abstract:
    Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or de-laying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The present invention is also directed to compositions and methods for improving insulin sensitivity in an animal or for preventing or delaying the onset of insulin resistance in an animal. Also provided are compositions and methods for treating or preventing a metabolic condition in an animal. The metabolic condition may be, e.g., diabetes or obesity.
  • Compounds And Methods For Modulating Gene Expression

    view source
  • US Patent:
    2008001, Jan 17, 2008
  • Filed:
    May 7, 2007
  • Appl. No.:
    11/745429
  • Inventors:
    Sanjay Bhanot - Carlsbad CA,
    Richard Geary - Carlsbad CA,
    Robert McKay - Poway CA,
    Brett Monia - Encinitas CA,
    Punit Seth - San Marcos CA,
    Andrew Siwkowski - Carlsbad CA,
    Eric Swayze - Carlsbad CA,
    Edward Wancewicz - Poway CA,
  • International Classification:
    A61K 48/00
    A61P 43/00
    C07H 21/04
    C12N 15/87
  • US Classification:
    514044000, 435455000, 536024500
  • Abstract:
    The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
  • Modulation Of Glucagon Receptor Expression

    view source
  • US Patent:
    2007023, Oct 11, 2007
  • Filed:
    Apr 5, 2007
  • Appl. No.:
    11/697273
  • Inventors:
    Sanjay Bhanot - Carlsbad CA,
    Susan Freier - San Diego CA,
    Kenneth Dobie - Del Mar CA,
    Robert McKay - Poway CA,
  • International Classification:
    A61K 31/711
    A61K 31/7105
    A61K 31/7125
    C07H 21/02
    C07H 21/04
  • US Classification:
    514044000, 536023100
  • Abstract:
    Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
  • Modulation Of Glucagon Receptor Expression

    view source
  • US Patent:
    2007023, Oct 11, 2007
  • Filed:
    Apr 5, 2007
  • Appl. No.:
    11/697270
  • Inventors:
    Sanjay Bhanot - Carlsbad CA,
    Susan Freier - San Diego CA,
    Kenneth Dobie - Del Mar CA,
    Robert McKay - Poway CA,
  • International Classification:
    A61K 31/711
    A61K 31/7105
    A61K 31/7125
    C07H 21/02
    C07H 21/04
  • US Classification:
    514044000, 536023100
  • Abstract:
    Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
  • Modulation Of Glucagon Receptor Expression

    view source
  • US Patent:
    2007023, Oct 11, 2007
  • Filed:
    Apr 5, 2007
  • Appl. No.:
    11/697262
  • Inventors:
    Sanjay Bhanot - Carlsbad CA,
    Susan Freier - San Diego CA,
    Kenneth Dobie - Del Mar CA,
    Robert McKay - Poway CA,
  • International Classification:
    A61K 31/711
    A61K 31/7105
    A61K 31/7125
    C07H 21/02
    C07H 21/04
  • US Classification:
    514044000, 536023100
  • Abstract:
    Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
  • Modulation Of Glucagon Receptor Expression

    view source
  • US Patent:
    2007008, Apr 19, 2007
  • Filed:
    Sep 19, 2006
  • Appl. No.:
    11/524041
  • Inventors:
    Brett Monia - Encinitas CA,
    Susan Freier - San Diego CA,
    Sanjay Bhanot - Carlsbad CA,
  • International Classification:
    A61K 48/00
    C07H 21/02
  • US Classification:
    514044000, 536023100
  • Abstract:
    Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides which have particular in vivo properties, targeted to nucleic acids encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for treatment of diseases are provided.

Business Records

Name / Title
Company / Classification
Phones & Addresses
Sanjay Bhanot
President
Heritage 1 Hour Cleaners
Dry Cleaners
8330 Macleod Tr SE, Calgary, AB T2H 2V2
403-2522188

Facebook

  • Sanjay Bhanot

    • Friends:
      Sarna Malhotra Pal, Timothy Krist, Jay Cleland, Carlos Monteagudo

Classmates

Sanjay Bhanot Photo 4

Kennedy-Western Universit...

view source
Graduates:
Sanjay Bhanot (2006-2010),
Bob Droege (2005-2006),
Mahmoud Fouad (1997-2003),
Denise Roe (2000-2004)

News

Isis Pharma's Diabetes Drug Takes Longer Than Expected To Work

Isis Pharma's diabetes drug takes longer than expected to work

view source
  • "In our past discussions with partners and Big Pharma companies, there has been continued interest in looking at this target for weight-loss independently, and so its something we're going to look at as we start longer term (mid-stage) studies,"Sanjay Bhanot, vice-president of clinical development
  • Date: Feb 03, 2015
  • Category: Health
  • Source: Google

Get Report for Sanjay Bhanot from Carlsbad, CA, age ~59
Control profile